Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $63,619 | $30,617 | $31,312 |
| G&A Expenses | $18,770 | $9,272 | $6,344 |
| SG&A Expenses | $18,770 | $9,272 | $6,344 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $82,389 | $39,889 | $37,656 |
| Operating Income | -$82,389 | -$39,889 | -$37,656 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $14,581 | -$12,091 | -$188 |
| Pre-Tax Income | -$67,808 | -$51,980 | -$37,844 |
| Tax Expense | $187 | $5 | $1 |
| Net Income | -$67,995 | -$51,985 | -$37,845 |
| % Margin | – | – | – |
| EPS | -1.25 | -1 | -0.73 |
| % Growth | -25% | -37% | – |
| EPS Diluted | -1.25 | -1 | -0.73 |
| Weighted Avg Shares Out | 54,425 | 51,761 | 51,761 |
| Weighted Avg Shares Out Dil | 54,425 | 51,761 | 51,761 |
| Supplemental Information | – | – | – |
| Interest Income | $14,581 | $1,314 | $4 |
| Interest Expense | $0 | $0 | $112 |
| Depreciation & Amortization | $56 | $19 | $10 |
| EBITDA | -$82,333 | -$39,870 | -$37,722 |
| % Margin | – | – | – |